IIIB期ROS1阳性NSCLC:克唑替尼联合手术及中医治疗获超长PFS一例
本文报道一例小原发灶(11 mm×8 mm)但高恶性ROS1融合阳性非小细胞肺癌(NSCLC)伴纵隔及锁骨上淋巴结转移患者,经新辅助克唑替尼靶向治疗后行肺叶切除及淋巴结清扫,术后持续靶向联合中医辅助干预,获得62个月无进展生存(PFS),无耐药或明显副作用,末次随访2025年8月仍生存良好。
要点
- 小病灶高侵袭性ROS1阳性NSCLC可考虑新辅助靶向降期后手术。
- 术后靶向联合中医辅助可能延长PFS并改善耐受性。
- 该例PFS达62个月,远超指南推荐克唑替尼约20个月的中位真实世界PFS。
核心结论
- 小病灶高侵袭性ROS1阳性NSCLC经新辅助克唑替尼降期后手术,术后靶向联合中医辅助获62个月PFS且无耐药或明显副作用。
研究设计与样本
- 个案报道:一例小原发灶(11 mm×8 mm)ROS1融合阳性NSCLC伴纵隔及锁骨上淋巴结转移患者。
主要发现
- 新辅助克唑替尼后行肺叶切除及淋巴结清扫,术后持续靶向联合中医辅助,PFS达62个月。
- 治疗期间无耐药或明显副作用,末次随访2025年8月患者仍生存良好。
- 该例PFS远超指南推荐克唑替尼约20个月的中位真实世界PFS(rwPFS)。
关键数值与推荐
- 该例PFS为62个月,指南推荐克唑替尼的中位rwPFS约20个月。
临床怎么用
- 对小病灶高侵袭性ROS1阳性NSCLC可探索新辅助靶向降期后手术。
- 术后可考虑靶向联合中医辅助以延长生存并改善耐受性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
This article reports a case of a patient with small primary foci (11 mm*8 mm), highly malignant ROS1 fusion-positive non-small cell lung cancer (NSCLC) with mediastinal and supraclavicular lymph node metastases. After neoadjuvant crizotinib targeted therapy, the patient underwent lobectomy and lymph node dissection. Postoperatively, continuous targeted therapy combined with Traditional Chinese Medicine (TCM) adjuvant intervention achieved an extremely prolonged 62-month progression-free survival (PFS) without drug resistance or obvious side effects, compared to the median real-world PFS (rwPFS) of approximately 20 months for guideline-recommended crizotinib treatment. The last follow-up in August 2025 showed the patient remained in good survival status. This case highlights a novel strategy of neoadjuvant targeted downstaging followed by surgical resection for small-lesion, highly invasive NSCLC, as well as the potential value of integrating postoperative Chinese-Western medicine management for long-term survival and treatment tolerance.
引用
- Zhu Y, Zhang H, Han ZX, et al. Stage IIIB ROS1-Positive NSCLC management: crizotinib + surgery + TCM achieves exceptionally prolonged PFS (a case report). Front Pharmacol. 2026. PMID: 41773166. doi:10.3389/fphar.2026.1693269
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。